Ginkgo Bioworks Holdings (DNA) said Thursday the Advanced Research Projects Agency for Health has awarded the company and its partners a $29 million contract for a project to stabilize and reshore supply chains for essential pharmaceuticals.
The company and its partners, Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals and Isolere Bio by Donaldson, will use wheat germ cell-free expression systems to develop distributed manufacturing of essential medicines under the two-year program, Ginkgo Bioworks said.
The strategy moves the production of active pharmaceutical ingredients to a "robust" and decentralized system from "fragile" global supply chains, the company said.
Price: 6.56, Change: -0.23, Percent Change: -3.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。